Fremanezumab: latest news - GoINPHARMA
Wednesday, 23 January 2019 - 23:12


FDA accepts BLA for Teva’s fremanezumab

Teva Pharmaceutical today has announced that FDA has accepted its BLA (Biologics License Application) for fremanezumab, an anti-CGRP monoclonal antibody for the preventive treatment of migraine. Additionally, the Administration has granted Fast Track Designation to the product for the prevention…